Panacea Biotec gets warning letter from USFDA for Baddi plant
5th Oct 2020

Panacea Biotec has received warning letter from US Food and Drug Administration (USFDA) for violating current good manufacturing practice norms at its Baddi plant in Himachal Pradesh. This warning letter summarises significant violations of current good manufacturing practice (CGMP) regulations for finished pharmaceuticals. Because methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, company’s drug products are adulterated. The significant violations included company's failure to establish laboratory controls.

Panacea Biotec is a leading research based Biotechnology Company with established research, manufacturing and marketing capabilities.